quinazolines has been researched along with (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, L; Liu, Y; Wang, G; Wei, F; Zhang, P; Zhang, Y | 1 |
1 other study(ies) available for quinazolines and (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
| Article | Year |
|---|---|
mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Forkhead Transcription Factors; Humans; Morpholines; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |